April 6 (Reuters) - M Pharmaceutical Inc MQ.CD
* Signs definitive agreement to acquire reformulated
orlistat for weight loss from Chelatexx LLC
* Says addition of C-103 provides a novel weight loss
pharmaceutical product to M Pharma pipeline
* Entered into a definitive agreement to acquire assets from
Chelatexx LLC related to a reformulated version of orlistat
* Company also announced it was undertaking a non-brokered
private placement of up to $700,000
Source text for Eikon: ID:nCCN4Bxgw2
Further company coverage: MQ.CD
(Bengaluru Newsroom: +1-646-223-8780)